A potent necroptosis inhibitor. Displays higher activity in inhibiting necroptosis in Jurkat cells than Nec-1 (Cat. No. 1864) (EC₅₀ = 210 nM versus EC₅₀ = 490 nM), as well as showing no nonspecific cytotoxicity at high concentrations (~100 mM). More useful for in-cell and in vivo experiments compared to Nec-1.
Abstract
Abdominal aortic aneurysm (AAA) is a common aortic disease with a progressive nature. There is no approved pharmacological treatment that would effectively slow the growth of the aneurysm or prevent rupture. Necrosis is a form of programmed necrosis that is regulated by receptor-interacting protein kinases (RIPs). We have recently shown that a lack of RIP3 in mice prevented aneurysm formation.
The aim of this study is to test whether disruptive necrosis affects the progression of existing aneurysms using RIP1 inhibitors Necrostatin-1 (Nec-1) and optimized forms of Nec-1, 7-Cl-O-Nec-1 (Nec-1 s). Seven days after induction of the aneurysm by elastase perfusion, mice were randomly administered DMSO, Nec-1 (3.2 mg / kg / day) and Nec-1s (1.6 mg / kg / day) by intraperitoneal injection. After sacrifice on day 14 of postaneurysm induction, the aortic expansion in the Nec-1s group (64.12 ± 4.80%) was significantly smaller than in the DMSO group (172.80 ± 13.68%) (P <0.05).
The mean aortic diameter of Nec-1-treated mice appeared to be smaller (121.60 ± 10.40%) than the DMSO group, although the difference was not statistically significant (P = 0.1). Histologically, the aortic structure of Nec-1s-treated mice appeared normal, with continuous and organized elastin layers and rich SMCs expressing αActin. In addition, Nect-1 treatment reduced macrophage infiltration and MMP9 accumulation and increased tropoelastin and lysyl oxidase aortic levels. Together, our data suggest that pharmacological inhibition of necrosis by Nec-1 stabilizes pre-existing aneurysms by reducing inflammation and promoting connective tissue repair.
Description: Recombinant stable MM.1S cell line constitutively expressing a firefly luciferase and enhanced GFP (eGFP) cassette driven by a CMV promoter.
Microtubule Associated Protein 1S (MAP1S) Antibody (HRP)
-RSL3)
-(-)-alpha-Pinene)
‐(+)‐10‐CAMPHORSULFONIC ACID)
-3-aminocyclohexanol)
-3-Aminocyclohexanol)
)
 hydrochloride))
-ACPD)
-DT-061)
-PIM447 (dihydrochloride))
 Antibody)
)
-Methyl 3-aminocyclopentanecarboxylate hydrochloride)
-2-Aminocyclopentanol hydrochloride)
-2-(Boc-amino)cyclopentanecarboxylicacid)
-3-Hydroxycyclopentylcarbamate)
 Antibody (HRP))
 Antibody (FITC))
 Antibody (Biotin))
-(+)-N-p-Tosyl-1,2-diphenylethylenediamine)
-2-Phenylcyclopropane-1-carboxylic acid)
 Antibody Pair)
 ELISA Kit)
